{"nctId":"NCT01246479","briefTitle":"Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study","startDateStruct":{"date":"2010-10"},"conditions":["Japanese Encephalitis"],"count":23,"armGroups":[{"label":"No treatment","type":"OTHER","interventionNames":["Procedure: Blood draw","Biological: IC51 has given in the parent study IC51-322"]}],"interventions":[{"name":"Blood draw","otherNames":[]},{"name":"IC51 has given in the parent study IC51-322","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects who have received two vaccinations in study IC51 322. (2) Subjects who were enrolled as part of the immunogenicity subgroup of study IC51-322.\n* Male or female healthy subjects aged ≥ 9 months to \\< 21 years at the time of enrolment into this study.\n* Written informed consent by the subject, the subject's legal representative(s), according to local requirements, and written informed assent of the subject, if applicable.\n\nExclusion Criteria:\n\n* History of or clinical manifestation of any Flavivirus disease during study IC51-322.\n* Vaccination against JE virus (JEV) (except with IC51) at any time prior or planned during this study.\n* Participation in another study with an investigational product during study IC51-322 or IC51-324.\n* History of or development of any immunodeficiency including post-organtransplantation after inclusion into study IC51-322.\n* History of or development of an autoimmune disease during study IC51-322.\n* Administration of chronic (defined as more than 14 days) immunosuppressants or other immune-modifying medications started during study IC51-322 up to first visit of study IC51-324. (For corticosteroids this means prednisone or equivalent at \\>= 0.05 mg/kg/day. Topical or inhaled steroids are allowed).\n* Known infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV).\n* Illicit drug use and/or a history of drug or alcohol addiction and/or current drug or alcohol addiction.\n* Inability or unwillingness by the legal representative(s) and/or the subject (where applicable) to provide informed consent/assent and to abide by the requirements of the study.\n* Persons who are committed to an institution (by virtue of an order issued either by the judicial or the administrative authorities).","healthyVolunteers":true,"sex":"ALL","minimumAge":"9 Months","maximumAge":"20 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Rate of Subjects With PRNT50 Titers of ≥ 1:10 at Month 12 After the First IC51 Vaccination (in Study IC51-322)","description":"Rate of subjects with PRNT50 titers of ≥ 1:10 at Month 12 after the first IC51 vaccination (in study IC51-322)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89.5","spread":null}]}]}]},{"type":"SECONDARY","title":"GMT for JEV Neutralizing Antibodies Measured Using the PRNT at Month 12, 24 and 36 After the First IC51 Vaccination (in Study IC51-322)","description":"GMT for JEV neutralizing antibodies measured using the PRNT at Month 12, 24 and 36 after the first IC51 vaccination (in study IC51-322)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Rate of Subjects With PRNT50 Titers of ≥ 1:10 at Months 24 and 36 After the First IC51 Vaccination (in Study IC51-322)","description":"Rate of subjects with PRNT50 titers of ≥ 1:10 at Months 24 and 36 after the first IC51 vaccination (in study IC51-322)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Rate of Subjects With SAEs Following Immunization up to Months 12, 24 and 36 After the First IC51 Vaccination (in Study IC51-322)","description":"Rate of subjects with SAEs following immunization up to Months 12, 24 and 36 after the first IC51 vaccination (in study IC51-322)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Rate of Subjects With AEs and Medically Attended AEs up to Months 12, 24 and 36 After the First IC51 Vaccination (in Study IC51-322).","description":"Rate of subjects with AEs and medically attended AEs up to Months 12, 24 and 36 after the first IC51 vaccination (in study IC51-322).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":23},"commonTop":["Otitis media acute","Pharyngitis streptococcal","Diarrhoea","Skin papilloma"]}}}